Skip to main content

Cancer Cachexia Market Size [2021-2028] | is Projected to Reach USD 2.93 Billion

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others.

Pune, India, Dec. 16, 2021 (GLOBE NEWSWIRE) — The Cancer Cachexia Market is anticipated to gain traction from the rising shift of the healthcare providers towards combination therapies. Such therapies are aiding in improving the lean body mass (LBM) of patients. This information is given by Fortune Business Insights™ in a recently published report, titled, “Cancer Cachexia Market Size, Share & Covid-19 Impact Analysis, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The report further states that this market size was USD 2.02 billion in 2019 and is projected to reach USD 2.93 billion by 2027, thereby exhibiting a CAGR of 4.8% during the forecast period.


Request a Sample Copy of the Research Report @

https://www.fortunebusinessinsights.com/enquiry/sample/cancer-cachexia-market-103262


Report Scope & Segmentation

Report CoverageDetails
Forecast Period2020-2027
Forecast Period 2021 to 2028 CAGR4.8%
2027 Value ProjectionUSD 2.93 Billion
Base Year2019
Market Size in 2021USD 2.02 Billion
Historical Data for2016 to 2018
No. of Pages120
Segments coveredBy Product Analysis, By Distribution Channel Analysis, By Geography.
Growth DriversThe rising prevalence of cachexia, as well as cancer is further creating a huge patient pool requiring treatment for the same.
World Health Organization (WHO) declared that around 18.1 million new cases of cancer were reported in 2018 globally. These researches prove that the demand for cancer cachexia therapeutics is set to surge in the near future.


To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit:  https://www.fortunebusinessinsights.com/cancer-cachexia-market-103262


Rising Incidence of Cancer Cachexia to Skyrocket Demand

The rising prevalence of cachexia, as well as cancer is further creating a huge patient pool requiring treatment for the same. The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD), a non-profit organization, mentioned in a report that in the developing nations, approximately 0.5-1.0% of the total population suffer from cancer cachexia. Besides, the World Health Organization (WHO) declared that around 18.1 million new cases of cancer were reported in 2018 globally. These researches prove that the demand for cancer cachexia therapeutics is set to surge in the near future. However, the strict government rules and regulations regarding the clinical trials of new candidates may hamper the cancer cachexia market growth in the coming years.

Progestogens Segment to Dominate Owing to Their Cost-effective Nature

In terms of products, the market is segregated into combination therapies, corticosteroids, progestogens, and others. Out of these, the progestogens segment is in the dominant position in terms of the cancer cachexia market share. This growth is attributable to the higher efficiency of progestogens in the treatment of cancer cachexia. They are also cost-effective, as compared to the other products.


Ask for Customization @

https://www.fortunebusinessinsights.com/enquiry/customization/cancer-cachexia-market-103262


North America to Lead Backed by Presence of Favorable Reimbursement Policies

Geographically, in 2019, North America procured USD 0.80 billion in terms of revenue. The region is likely to lead the market throughout the forecast period. This growth is attributable to the increasing awareness programs amongst the masses about the benefits of supportive care for cancer. Apart from this, the presence of favorable reimbursement policies in the developed countries, such as Canada and the U.S. would contribute to the growth of the market in this region. Europe is expected to exhibit a considerable CAGR in the coming years owing to the high demand for therapeutics for the treatment of cancer cachexia. Asia Pacific, on the other hand, is set to grow significantly fueled by the increasing investments by the prominent companies present in the region in research and development activities.


Speak to Analyst in case of any Queries @

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cancer-cachexia-market-103262


Competitive Landscape-

Key Players to Invest Hefty Amounts in R&D for Creating Novel Drugs

The global market is presently underpenetrated with the presence of very few companies worldwide. This is mainly occurring because of the lack of approved therapeutics for the treatment of cancer cachexia. However, some of the companies are investing in R&D activities to come up with new drug candidates. Below are two of the latest industry developments:

  • July 2019: Mylan N.V., and Pfizer Inc., entered into a definitive agreement to form a new company named Viatris. It would help both companies to fulfill the growing demand for innovative treatment options from the patients, as well as broaden their access to medicines.
  • November 2019: Bristol-Myers Squibb Company successfully acquired Celgene Corporation to create a strong biopharma company. As per the officials of Bristol, its expertise in the fields of cardiovascular disease, hematology, immunology, and oncology would aid in transforming the lives of the patients through technological advancements.

Fortune Business Insights™ presents a list of all the providers of cancer cachexia therapeutics operating in the global market. They are as follows:

  • Bristol-Myers Squibb Company, New York, U.S.
  • ANI Pharmaceuticals, Inc., Baudette, U.S.
  • Merck & Co., Inc., Kenilworth, U.S.
  • Hikma Pharmaceuticals PLC, London, U.K.
  • Mylan N.V., Pennsylvania, U.S.
  • AbbVie, Inc., North Chicago, U.S.
  • Pfizer Inc., New York, U.S.
  • Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com



Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.